| Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis MP Sormani, N De Rossi, I Schiavetti, L Carmisciano, C Cordioli, L Moiola, ... Annals of neurology 89 (4), 780-789, 2021 | 472 | 2021 |
| Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview LE Adinolfi, R Nevola, G Lus, L Restivo, B Guerrera, C Romano, ... World journal of gastroenterology: WJG 21 (8), 2269, 2015 | 210 | 2015 |
| Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies MP Sormani, M Inglese, I Schiavetti, L Carmisciano, A Laroni, C Lapucci, ... EBioMedicine 72, 2021 | 190 | 2021 |
| Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis M Trojano, F Pellegrini, D Paolicelli, A Fuiani, GB Zimatore, C Tortorella, ... Annals of neurology 66 (4), 513-520, 2009 | 171 | 2009 |
| Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity F Patti, S Messina, C Solaro, MP Amato, R Bergamaschi, S Bonavita, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (9), 944-951, 2016 | 110 | 2016 |
| DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France MP Sormani, M Salvetti, P Labauge, I Schiavetti, H Zephir, L Carmisciano, ... Annals of clinical and translational neurology 8 (8), 1738-1744, 2021 | 105 | 2021 |
| Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype MAB Melone, A Tessa, S Petrini, G Lus, S Sampaolo, G di Fede, ... Archives of neurology 61 (2), 269-272, 2004 | 97 | 2004 |
| Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing—remitting active multiple sclerosis patients: a longitudinal controlled trial of combination … R Lanzillo, G Orefice, M Quarantelli, C Rinaldi, A Prinster, G Ventrella, ... Multiple Sclerosis Journal 16 (4), 450-454, 2010 | 89 | 2010 |
| Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis P Iaffaldano, G Lucisano, C Pozzilli, V Brescia Morra, A Ghezzi, ... Brain 138 (11), 3275-3286, 2015 | 85 | 2015 |
| Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases A Ghezzi, C Pozzilli, LME Grimaldi, L Moiola, V Brescia-Morra, A Lugaresi, ... Multiple Sclerosis Journal 19 (8), 1106-1112, 2013 | 84 | 2013 |
| Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies P Iaffaldano, G Lucisano, F Caputo, D Paolicelli, F Patti, M Zaffaroni, ... Therapeutic Advances in Neurological Disorders 14, 17562864211019574, 2021 | 74 | 2021 |
| The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests F Saccà, T Costabile, A Carotenuto, R Lanzillo, M Moccia, C Pane, ... Multiple Sclerosis Journal 23 (9), 1289-1296, 2017 | 68 | 2017 |
| Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis MP Amato, M Fonderico, E Portaccio, L Pastò, L Razzolini, E Prestipino, ... Brain 143 (10), 3013-3024, 2020 | 64 | 2020 |
| Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised … JF Foley, G Defer, LZ Ryerson, JA Cohen, DL Arnold, H Butzkueven, ... The Lancet Neurology 21 (7), 608-619, 2022 | 61 | 2022 |
| Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy MP Sormani, I Schiavetti, M Inglese, L Carmisciano, A Laroni, C Lapucci, ... EBioMedicine 80, 2022 | 59 | 2022 |
| Normalization of short‐chain acylcoenzyme a dehydrogenase after riboflavin treatment in a girl with multiple acylcoenzyme a dehydrogenase—deficient myopathy S Didonato, C Gellera, D Peluchetti, G Uziel, A Antonelli, G Lus, ... Annals of Neurology: Official Journal of the American Neurological …, 1989 | 55 | 1989 |
| No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study L Prosperini, P Annovazzi, L Boffa, MC Buscarinu, A Gallo, M Matta, ... Journal of neurology 265, 2851-2860, 2018 | 54 | 2018 |
| Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study E Portaccio, A Bellinvia, M Fonderico, L Pastò, L Razzolini, R Totaro, ... Brain 145 (8), 2796-2805, 2022 | 53 | 2022 |
| Extending the interval of natalizumab dosing: is efficacy preserved? M Clerico, SF De Mercanti, A Signori, M Iudicello, C Cordioli, E Signoriello, ... Neurotherapeutics 17, 200-207, 2020 | 52 | 2020 |
| Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study P Annovazzi, M Capobianco, L Moiola, F Patti, J Frau, A Uccelli, ... Journal of neurology 263, 1727-1735, 2016 | 47 | 2016 |
